Develops DNA-based immunotherapies and vaccines for infectious diseases and cancer, focusing on novel approaches to enhance immune responses.
Inovio Pharmaceuticals, Inc., a pioneering biotechnology company headquartered in Plymouth Meeting, Pennsylvania, is dedicated to advancing the discovery, development, and commercialization of DNA medicines. Specializing in treatments and preventive measures against human papillomavirus (HPV), cancer, and infectious diseases, Inovio employs its proprietary DNA medicines platform featuring SynCon technology. This platform allows precise identification and optimization of DNA sequences targeting specific antigens, complemented by the CELLECTRA smart devices technology for effective DNA plasmid delivery.
The company is actively involved in conducting clinical studies across a wide spectrum of conditions. These include HPV-associated precancers like cervical, vulvar, and anal dysplasia, as well as various HPV-associated cancers such as head and neck, cervical, anal, penile, vulvar, and vaginal cancers. Inovio also explores treatments for other HPV-related disorders, glioblastoma multiforme, prostate cancer, HIV, Ebola, Middle East Respiratory Syndrome (MERS), Lassa fever, and more.
Inovio Pharmaceuticals collaborates extensively with prominent partners and institutions, including AstraZeneca, Bill & Melinda Gates Foundation, DARPA, NIH, Regeneron Pharmaceuticals, and University of Pennsylvania, among others. Notably, Inovio has agreements with Richter-Helm BioLogics GmbH & Co. KG for supporting its investigational DNA vaccine INO-4800 for COVID-19, highlighting its commitment to addressing global health challenges through innovative vaccine solutions. Established in 1979, Inovio Pharmaceuticals continues to lead the way in advancing DNA medicine technologies to improve human health worldwide.